The Real-World Effectiveness and Tolerability of a Soothing Cream Containing the Postbiotic Aquaphilus dolomiae Extract-G2 for Skin Healing
Introduction In vitro and pre-marketing clinical data have shown the healing properties of a postbiotic extract from Aquaphilus dolomiae (ADE-G2). The effectiveness and tolerability of an ADE-G2-based cream were therefore evaluated for the management of minor skin impairment and wound healing in a l...
Saved in:
| Published in | Dermatology and therapy Vol. 14; no. 3; pp. 697 - 712 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Cheshire
Springer Healthcare
01.03.2024
Springer Springer Nature B.V Adis, Springer Healthcare |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Introduction
In vitro and pre-marketing clinical data have shown the healing properties of a postbiotic extract from
Aquaphilus dolomiae
(ADE-G2). The effectiveness and tolerability of an ADE-G2-based cream were therefore evaluated for the management of minor skin impairment and wound healing in a large population of subjects in routine clinical practice.
Methods
A real-world, international, pre-post comparative study was conducted in infants, children, and adults with various types of superficial skin impairment who used the study product daily for around 3 weeks according to their dermatologist’s advice. Immediate and follow-up changes in dermatologic signs and symptoms were assessed through clinical scoring. User satisfaction, overall product effectiveness, and tolerability were also evaluated. Analyses were performed in the whole study population and in subject subgroups according to skin impairment type and age.
Results
Overall, 1317 subjects (83.1% adults, 72.0% female) were included. Dermatologists reported effectiveness and “good” or “very good” tolerability of the cream in 93.8% (1221/1302) and 98.5% (1278/1297) of subjects, respectively. Immediate symptom relief after the first application was reported by 88.3% (849/962) of subjects. After several weeks of regular use (16.7 ± 11.6 days), dermatologic signs and symptoms significantly improved in the whole study population and in the subgroups, with mean decreases in severity scores ranging from –34.5% to –92.5% (
p
< 0.0001). The smallest improvements were found in subjects with oncologic treatment-related skin impairment. At study end, most users (> 95%) were “very satisfied” or “satisfied” with the cream and found that skin healing was rapid and of good quality.
Conclusion
The ADE-G2-based cream proved to be effective and well tolerated in real-life conditions for the management of minor skin impairment in a large and varied cohort of subjects. This product, used as a standalone or adjunctive regimen, can help accelerate the healing of various types of superficial skin impairment. |
|---|---|
| AbstractList | IntroductionIn vitro and pre-marketing clinical data have shown the healing properties of a postbiotic extract from Aquaphilus dolomiae (ADE-G2). The effectiveness and tolerability of an ADE-G2-based cream were therefore evaluated for the management of minor skin impairment and wound healing in a large population of subjects in routine clinical practice.MethodsA real-world, international, pre-post comparative study was conducted in infants, children, and adults with various types of superficial skin impairment who used the study product daily for around 3 weeks according to their dermatologist’s advice. Immediate and follow-up changes in dermatologic signs and symptoms were assessed through clinical scoring. User satisfaction, overall product effectiveness, and tolerability were also evaluated. Analyses were performed in the whole study population and in subject subgroups according to skin impairment type and age.ResultsOverall, 1317 subjects (83.1% adults, 72.0% female) were included. Dermatologists reported effectiveness and “good” or “very good” tolerability of the cream in 93.8% (1221/1302) and 98.5% (1278/1297) of subjects, respectively. Immediate symptom relief after the first application was reported by 88.3% (849/962) of subjects. After several weeks of regular use (16.7 ± 11.6 days), dermatologic signs and symptoms significantly improved in the whole study population and in the subgroups, with mean decreases in severity scores ranging from –34.5% to –92.5% (p < 0.0001). The smallest improvements were found in subjects with oncologic treatment-related skin impairment. At study end, most users (> 95%) were “very satisfied” or “satisfied” with the cream and found that skin healing was rapid and of good quality.ConclusionThe ADE-G2-based cream proved to be effective and well tolerated in real-life conditions for the management of minor skin impairment in a large and varied cohort of subjects. This product, used as a standalone or adjunctive regimen, can help accelerate the healing of various types of superficial skin impairment. Introduction In vitro and pre-marketing clinical data have shown the healing properties of a postbiotic extract from Aquaphilus dolomiae (ADE-G2). The effectiveness and tolerability of an ADE-G2-based cream were therefore evaluated for the management of minor skin impairment and wound healing in a large population of subjects in routine clinical practice. Methods A real-world, international, pre-post comparative study was conducted in infants, children, and adults with various types of superficial skin impairment who used the study product daily for around 3 weeks according to their dermatologist’s advice. Immediate and follow-up changes in dermatologic signs and symptoms were assessed through clinical scoring. User satisfaction, overall product effectiveness, and tolerability were also evaluated. Analyses were performed in the whole study population and in subject subgroups according to skin impairment type and age. Results Overall, 1317 subjects (83.1% adults, 72.0% female) were included. Dermatologists reported effectiveness and “good” or “very good” tolerability of the cream in 93.8% (1221/1302) and 98.5% (1278/1297) of subjects, respectively. Immediate symptom relief after the first application was reported by 88.3% (849/962) of subjects. After several weeks of regular use (16.7 ± 11.6 days), dermatologic signs and symptoms significantly improved in the whole study population and in the subgroups, with mean decreases in severity scores ranging from –34.5% to –92.5% ( p < 0.0001). The smallest improvements were found in subjects with oncologic treatment-related skin impairment. At study end, most users (> 95%) were “very satisfied” or “satisfied” with the cream and found that skin healing was rapid and of good quality. Conclusion The ADE-G2-based cream proved to be effective and well tolerated in real-life conditions for the management of minor skin impairment in a large and varied cohort of subjects. This product, used as a standalone or adjunctive regimen, can help accelerate the healing of various types of superficial skin impairment. In vitro and pre-marketing clinical data have shown the healing properties of a postbiotic extract from Aquaphilus dolomiae (ADE-G2). The effectiveness and tolerability of an ADE-G2-based cream were therefore evaluated for the management of minor skin impairment and wound healing in a large population of subjects in routine clinical practice.INTRODUCTIONIn vitro and pre-marketing clinical data have shown the healing properties of a postbiotic extract from Aquaphilus dolomiae (ADE-G2). The effectiveness and tolerability of an ADE-G2-based cream were therefore evaluated for the management of minor skin impairment and wound healing in a large population of subjects in routine clinical practice.A real-world, international, pre-post comparative study was conducted in infants, children, and adults with various types of superficial skin impairment who used the study product daily for around 3 weeks according to their dermatologist's advice. Immediate and follow-up changes in dermatologic signs and symptoms were assessed through clinical scoring. User satisfaction, overall product effectiveness, and tolerability were also evaluated. Analyses were performed in the whole study population and in subject subgroups according to skin impairment type and age.METHODSA real-world, international, pre-post comparative study was conducted in infants, children, and adults with various types of superficial skin impairment who used the study product daily for around 3 weeks according to their dermatologist's advice. Immediate and follow-up changes in dermatologic signs and symptoms were assessed through clinical scoring. User satisfaction, overall product effectiveness, and tolerability were also evaluated. Analyses were performed in the whole study population and in subject subgroups according to skin impairment type and age.Overall, 1317 subjects (83.1% adults, 72.0% female) were included. Dermatologists reported effectiveness and "good" or "very good" tolerability of the cream in 93.8% (1221/1302) and 98.5% (1278/1297) of subjects, respectively. Immediate symptom relief after the first application was reported by 88.3% (849/962) of subjects. After several weeks of regular use (16.7 ± 11.6 days), dermatologic signs and symptoms significantly improved in the whole study population and in the subgroups, with mean decreases in severity scores ranging from -34.5% to -92.5% (p < 0.0001). The smallest improvements were found in subjects with oncologic treatment-related skin impairment. At study end, most users (> 95%) were "very satisfied" or "satisfied" with the cream and found that skin healing was rapid and of good quality.RESULTSOverall, 1317 subjects (83.1% adults, 72.0% female) were included. Dermatologists reported effectiveness and "good" or "very good" tolerability of the cream in 93.8% (1221/1302) and 98.5% (1278/1297) of subjects, respectively. Immediate symptom relief after the first application was reported by 88.3% (849/962) of subjects. After several weeks of regular use (16.7 ± 11.6 days), dermatologic signs and symptoms significantly improved in the whole study population and in the subgroups, with mean decreases in severity scores ranging from -34.5% to -92.5% (p < 0.0001). The smallest improvements were found in subjects with oncologic treatment-related skin impairment. At study end, most users (> 95%) were "very satisfied" or "satisfied" with the cream and found that skin healing was rapid and of good quality.The ADE-G2-based cream proved to be effective and well tolerated in real-life conditions for the management of minor skin impairment in a large and varied cohort of subjects. This product, used as a standalone or adjunctive regimen, can help accelerate the healing of various types of superficial skin impairment.CONCLUSIONThe ADE-G2-based cream proved to be effective and well tolerated in real-life conditions for the management of minor skin impairment in a large and varied cohort of subjects. This product, used as a standalone or adjunctive regimen, can help accelerate the healing of various types of superficial skin impairment. Introduction In vitro and pre-marketing clinical data have shown the healing properties of a postbiotic extract from Aquaphilus dolomiae (ADE-G2). The effectiveness and tolerability of an ADE-G2-based cream were therefore evaluated for the management of minor skin impairment and wound healing in a large population of subjects in routine clinical practice. Methods A real-world, international, pre-post comparative study was conducted in infants, children, and adults with various types of superficial skin impairment who used the study product daily for around 3 weeks according to their dermatologist's advice. Immediate and follow-up changes in dermatologic signs and symptoms were assessed through clinical scoring. User satisfaction, overall product effectiveness, and tolerability were also evaluated. Analyses were performed in the whole study population and in subject subgroups according to skin impairment type and age. Results Overall, 1317 subjects (83.1% adults, 72.0% female) were included. Dermatologists reported effectiveness and "good" or "very good" tolerability of the cream in 93.8% (1221/1302) and 98.5% (1278/1297) of subjects, respectively. Immediate symptom relief after the first application was reported by 88.3% (849/962) of subjects. After several weeks of regular use (16.7 ± 11.6 days), dermatologic signs and symptoms significantly improved in the whole study population and in the subgroups, with mean decreases in severity scores ranging from -34.5% to -92.5% (p 95%) were "very satisfied" or "satisfied" with the cream and found that skin healing was rapid and of good quality. Conclusion The ADE-G2-based cream proved to be effective and well tolerated in real-life conditions for the management of minor skin impairment in a large and varied cohort of subjects. This product, used as a standalone or adjunctive regimen, can help accelerate the healing of various types of superficial skin impairment. In vitro and pre-marketing clinical data have shown the healing properties of a postbiotic extract from Aquaphilus dolomiae (ADE-G2). The effectiveness and tolerability of an ADE-G2-based cream were therefore evaluated for the management of minor skin impairment and wound healing in a large population of subjects in routine clinical practice. A real-world, international, pre-post comparative study was conducted in infants, children, and adults with various types of superficial skin impairment who used the study product daily for around 3 weeks according to their dermatologist's advice. Immediate and follow-up changes in dermatologic signs and symptoms were assessed through clinical scoring. User satisfaction, overall product effectiveness, and tolerability were also evaluated. Analyses were performed in the whole study population and in subject subgroups according to skin impairment type and age. Overall, 1317 subjects (83.1% adults, 72.0% female) were included. Dermatologists reported effectiveness and "good" or "very good" tolerability of the cream in 93.8% (1221/1302) and 98.5% (1278/1297) of subjects, respectively. Immediate symptom relief after the first application was reported by 88.3% (849/962) of subjects. After several weeks of regular use (16.7 ± 11.6 days), dermatologic signs and symptoms significantly improved in the whole study population and in the subgroups, with mean decreases in severity scores ranging from -34.5% to -92.5% (p 95%) were "very satisfied" or "satisfied" with the cream and found that skin healing was rapid and of good quality. The ADE-G2-based cream proved to be effective and well tolerated in real-life conditions for the management of minor skin impairment in a large and varied cohort of subjects. This product, used as a standalone or adjunctive regimen, can help accelerate the healing of various types of superficial skin impairment. In vitro and pre-marketing clinical data have shown the healing properties of a postbiotic extract from Aquaphilus dolomiae (ADE-G2). The effectiveness and tolerability of an ADE-G2-based cream were therefore evaluated for the management of minor skin impairment and wound healing in a large population of subjects in routine clinical practice. A real-world, international, pre-post comparative study was conducted in infants, children, and adults with various types of superficial skin impairment who used the study product daily for around 3 weeks according to their dermatologist's advice. Immediate and follow-up changes in dermatologic signs and symptoms were assessed through clinical scoring. User satisfaction, overall product effectiveness, and tolerability were also evaluated. Analyses were performed in the whole study population and in subject subgroups according to skin impairment type and age. Overall, 1317 subjects (83.1% adults, 72.0% female) were included. Dermatologists reported effectiveness and "good" or "very good" tolerability of the cream in 93.8% (1221/1302) and 98.5% (1278/1297) of subjects, respectively. Immediate symptom relief after the first application was reported by 88.3% (849/962) of subjects. After several weeks of regular use (16.7 ± 11.6 days), dermatologic signs and symptoms significantly improved in the whole study population and in the subgroups, with mean decreases in severity scores ranging from -34.5% to -92.5% (p < 0.0001). The smallest improvements were found in subjects with oncologic treatment-related skin impairment. At study end, most users (> 95%) were "very satisfied" or "satisfied" with the cream and found that skin healing was rapid and of good quality. The ADE-G2-based cream proved to be effective and well tolerated in real-life conditions for the management of minor skin impairment in a large and varied cohort of subjects. This product, used as a standalone or adjunctive regimen, can help accelerate the healing of various types of superficial skin impairment. Abstract Introduction In vitro and pre-marketing clinical data have shown the healing properties of a postbiotic extract from Aquaphilus dolomiae (ADE-G2). The effectiveness and tolerability of an ADE-G2-based cream were therefore evaluated for the management of minor skin impairment and wound healing in a large population of subjects in routine clinical practice. Methods A real-world, international, pre-post comparative study was conducted in infants, children, and adults with various types of superficial skin impairment who used the study product daily for around 3 weeks according to their dermatologist’s advice. Immediate and follow-up changes in dermatologic signs and symptoms were assessed through clinical scoring. User satisfaction, overall product effectiveness, and tolerability were also evaluated. Analyses were performed in the whole study population and in subject subgroups according to skin impairment type and age. Results Overall, 1317 subjects (83.1% adults, 72.0% female) were included. Dermatologists reported effectiveness and “good” or “very good” tolerability of the cream in 93.8% (1221/1302) and 98.5% (1278/1297) of subjects, respectively. Immediate symptom relief after the first application was reported by 88.3% (849/962) of subjects. After several weeks of regular use (16.7 ± 11.6 days), dermatologic signs and symptoms significantly improved in the whole study population and in the subgroups, with mean decreases in severity scores ranging from –34.5% to –92.5% (p < 0.0001). The smallest improvements were found in subjects with oncologic treatment-related skin impairment. At study end, most users (> 95%) were “very satisfied” or “satisfied” with the cream and found that skin healing was rapid and of good quality. Conclusion The ADE-G2-based cream proved to be effective and well tolerated in real-life conditions for the management of minor skin impairment in a large and varied cohort of subjects. This product, used as a standalone or adjunctive regimen, can help accelerate the healing of various types of superficial skin impairment. |
| Audience | Academic |
| Author | Ortiz-Brugués, Ariadna Shi, Yuling Frasson, Nicolas Stennevin, Aline Lain, Edward |
| Author_xml | – sequence: 1 givenname: Yuling orcidid: 0000-0002-1273-7881 surname: Shi fullname: Shi, Yuling organization: Department of Dermatology, Shanghai Skin Disease Hospital and Institute of Psoriasis, Tongji University School of Medicine – sequence: 2 givenname: Edward orcidid: 0000-0002-3805-9441 surname: Lain fullname: Lain, Edward organization: Sanova Dermatology, Austin Institute for Clinical Research – sequence: 3 givenname: Nicolas orcidid: 0000-0003-0707-8735 surname: Frasson fullname: Frasson, Nicolas – sequence: 4 givenname: Ariadna orcidid: 0000-0001-6205-0941 surname: Ortiz-Brugués fullname: Ortiz-Brugués, Ariadna organization: Laboratoires Dermatologiques Avène, Pierre Fabre Dermo-Cosmétique – sequence: 5 givenname: Aline orcidid: 0009-0009-6733-9985 surname: Stennevin fullname: Stennevin, Aline email: aline.stennevin@pierre-fabre.com organization: Laboratoires Dermatologiques Avène, Pierre Fabre Dermo-Cosmétique |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38451421$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Us1uGyEYXFWpmjTNC_RQIfWSy6b8Luypiiw3iRSpVeOqR8SyYOOuwQEcOc_Qly62k6aOqsAB9DEzMB_ztjrwwZuqeo_gGYKQf0qIMMZqiGkNEUJtvX5VHWHUwrpFHB9s96QWGMHD6iSlOSyDw4YI9KY6JIIyRDE6qn5PZgZ8N2qof4Y49GBsrdHZ3RlvUgLK92ASBhNV5waX70GwQIGbEPLM-SkYRaMWYBR8Vs5vCrmIfQspdy5kp8H57UotZ25YJdCHISycMmC8zlHpXF9gYEMEN7-cB5fl_kJ_V722akjm5GE9rn58GU9Gl_X114ur0fl1rRsock0V5h1ulCYt6TlmHaUCNhpBq7nWkFre0F7otrFC275VWCOmKWk7qxoGiSXH1dVOtw9qLpfRLVS8l0E5uS2EOJUqlvcPRrYNYVarlglsKIdUCIY72nHWaAUFgkXr805rueoWptfGF3vDnuj-iXczOQ13EsG2YeUbisLpg0IMtyuTsly4pM0wKG_CKknclo8SHHJSoB-fQedhFX3plSQYU8gQbtgTaqqKA-dt2HR8IyrPueACQ0FFQZ39B1VmbxZOl6xZV-p7hA__Ov1r8TFLBSB2AB1DStFYqV1W2YWNcTcUx3KTXLlLrizJldvkynWh4mfUR_UXSWRHSgXspyY-deMF1h_DqP9l |
| CitedBy_id | crossref_primary_10_4103_MJD_MJD_20_24 |
| Cites_doi | 10.1007/s00253-022-12116-5 10.3390/microorganisms11061420 10.3390/nu13082666 10.1684/ejd.2017.2994 10.1051/medsci/20163211014 10.1111/jdv.17902 10.1684/ejd.2022.4355 10.1016/s0151-9638(08)70092-9 10.1111/jocd.12764 10.1371/journal.pone.0001393 10.1111/jdv.16477 10.1111/j.1468-3083.2010.03892.x 10.1111/j.1468-3083.2010.03775.x 10.1111/1462-2920.13926 10.1111/exd.12929 10.3390/cells11152439 10.3390/molecules27061849 10.1039/d3fo00152k 10.1111/pde.12786 10.1111/jdv.16641 10.2147/CCID.S157849 10.1371/journal.pone.0009351 10.3390/fermentation9030264 10.3390/ijms23094708 10.1155/2021/8577116 10.1007/s13555-022-00685-2 10.1002/jcb.25272 10.1097/00042728-200205000-00011 10.2147/ccid.S113180 10.1007/s13555-020-00415-6 10.3310/hta3172 10.1016/j.msec.2014.12.068 10.1007/s13555-019-0295-0 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024. corrected publication 2024 2024. The Author(s). COPYRIGHT 2024 Springer The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2024 |
| Copyright_xml | – notice: The Author(s) 2024. corrected publication 2024 – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 Springer – notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2024 |
| DBID | C6C AAYXX CITATION NPM 3V. 7X7 7XB 8AO 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1007/s13555-024-01119-x |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Pharma Collection ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2190-9172 |
| EndPage | 712 |
| ExternalDocumentID | oai_doaj_org_article_9635fca9582e47048852b4b756ca0810 PMC10965845 A787820848 38451421 10_1007_s13555_024_01119_x |
| Genre | Journal Article |
| GeographicLocations | France |
| GeographicLocations_xml | – name: France |
| GrantInformation_xml | – fundername: Pierre Fabre Dermo-Cosmétique |
| GroupedDBID | --- -A0 0R~ 2VQ 3V. 4.4 40G 53G 5VS 7X7 8AO 8FI 8FJ AAKDD AAKKN ABDBF ABEEZ ABUWG ACACY ACGFS ACMJI ACUHS ACULB ADBBV ADINQ ADRAZ AFGXO AFKRA AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BPHCQ BVXVI C24 C6C CCPQU DIK EBS EJD FYUFA GROUPED_DOAJ GX1 HMCUK HYE HZ~ IAO IHR ITC KQ8 LGEZI LOTEE M48 M~E NADUK NXXTH O9- OK1 PIMPY PQQKQ PROAC RNS RPM RSV SISQX SMD SOJ U2A UKHRP ~JE AAYXX CITATION PHGZM PHGZT NPM 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c608t-4a27b26ac393d725b44806c10fc7cc04f764d8c96f8cfd9a2c15c439bfa6503f3 |
| IEDL.DBID | M48 |
| ISSN | 2193-8210 |
| IngestDate | Wed Aug 27 01:16:37 EDT 2025 Thu Aug 21 18:35:22 EDT 2025 Fri Jul 11 07:31:10 EDT 2025 Fri Jul 25 09:03:26 EDT 2025 Tue Jun 17 22:11:33 EDT 2025 Tue Jun 10 21:07:59 EDT 2025 Mon Jul 21 06:05:28 EDT 2025 Thu Apr 24 22:51:22 EDT 2025 Tue Jul 01 03:55:19 EDT 2025 Fri Feb 21 02:42:13 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Skin healing Soothing Dermocosmetics Real-world study Postbiotics Skin impairment Aquaphilus dolomiae |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c608t-4a27b26ac393d725b44806c10fc7cc04f764d8c96f8cfd9a2c15c439bfa6503f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-0707-8735 0000-0001-6205-0941 0009-0009-6733-9985 0000-0002-1273-7881 0000-0002-3805-9441 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1007/s13555-024-01119-x |
| PMID | 38451421 |
| PQID | 3224051265 |
| PQPubID | 2034779 |
| PageCount | 16 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_9635fca9582e47048852b4b756ca0810 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10965845 proquest_miscellaneous_2942187073 proquest_journals_3224051265 gale_infotracmisc_A787820848 gale_infotracacademiconefile_A787820848 pubmed_primary_38451421 crossref_citationtrail_10_1007_s13555_024_01119_x crossref_primary_10_1007_s13555_024_01119_x springer_journals_10_1007_s13555_024_01119_x |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-03-01 |
| PublicationDateYYYYMMDD | 2024-03-01 |
| PublicationDate_xml | – month: 03 year: 2024 text: 2024-03-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Cheshire |
| PublicationPlace_xml | – name: Cheshire – name: Switzerland – name: Heidelberg |
| PublicationSubtitle | Research, treatment and aesthetic interventions in dermatology |
| PublicationTitle | Dermatology and therapy |
| PublicationTitleAbbrev | Dermatol Ther (Heidelb) |
| PublicationTitleAlternate | Dermatol Ther (Heidelb) |
| PublicationYear | 2024 |
| Publisher | Springer Healthcare Springer Springer Nature B.V Adis, Springer Healthcare |
| Publisher_xml | – name: Springer Healthcare – name: Springer – name: Springer Nature B.V – name: Adis, Springer Healthcare |
| References | Noizet, Bianchi, Galliano (CR12) 2020; 34 Dreifke, Jayasuriya, Jayasuriya (CR1) 2015; 48 Gao, Kumar, Jyot, Yu (CR7) 2010; 5 Kondo, Higa-Nakamine, Maeda (CR8) 2016; 117 Bianchi, Theunis, Casas (CR29) 2016; 33 Vendrely, Mayor-Ibarguren, Stennevin, Ortiz-Brugues (CR31) 2022; 12 Campolo, Gallo, Roviello (CR22) 2022 Brocario, Maurel, Kapoor, Lauze, Favrel (CR13) 2022; 32 Pinter, Thouvenin, Bacquey, Rossi, Nocera (CR14) 2019; 9 Bourrain, Villette, Nguyen, Lebaron (CR11) 2012; 62 Rawal, Ali (CR19) 2023; 14 Villaret, Lestienne, Vial (CR33) 2022; 36 Stedman, Nigro, Sansonetti (CR6) 2016; 32 Merial-Kieny, Castex-Rizzi, Selas, Mery, Guerrero (CR24) 2011; 25 Thouvenin, Bacquey, Nocera, Rossi (CR15) 2018; 17 Mangoni, McDermott, Zasloff (CR10) 2016; 25 Aries, Hernandez-Pigeon, Vaissière (CR27) 2016; 9 De Almeida, Antiga, Lulli (CR17) 2023; 11 Kolimi, Narala, Nyavanandi, Youssef, Dudhipala (CR4) 2022 Golkar, Ashoori, Heidari (CR21) 2021; 2021 De Rauglaudre, Courdi, Delaby-Chagrin (CR34) 2008; 135 Ribet, Mielewczyk, Sirvent, Georgescu, Rossi (CR25) 2018; 11 Deleuran, Georgescu, Jean-Decoster (CR30) 2020; 10 Parker, Lawson, Vaux, Pin (CR5) 2018; 20 Shaykhiev, Behr, Bals (CR9) 2008; 3 da Silva, de Melo Pereira, de Oliveira (CR16) 2023; 9 Korting, Schollmann, White (CR2) 2011; 25 Bradley, Cullum, Nelson (CR3) 1999; 3 Coppola, Avagliano, Sacchi (CR20) 2022 Nam, Kim, Baek, Kim (CR23) 2021 Fostini, Georgescu, Decoster, Girolomoni (CR28) 2017; 27 Sulimovic, Licu, Ledo (CR26) 2002; 28 Lestienne, Viode, Ceruti (CR32) 2020; 34 Duarte, Oliveira, Oliveira (CR18) 2022; 106 P Kolimi (1119_CR4) 2022 S Rawal (1119_CR19) 2023; 14 M Bourrain (1119_CR11) 2012; 62 MB Dreifke (1119_CR1) 2015; 48 VA da Silva (1119_CR16) 2023; 9 M Noizet (1119_CR12) 2020; 34 Y Kondo (1119_CR8) 2016; 117 M Duarte (1119_CR18) 2022; 106 A Brocario (1119_CR13) 2022; 32 A Parker (1119_CR5) 2018; 20 CV De Almeida (1119_CR17) 2023; 11 P Bianchi (1119_CR29) 2016; 33 G De Rauglaudre (1119_CR34) 2008; 135 M Campolo (1119_CR22) 2022 R Shaykhiev (1119_CR9) 2008; 3 C Merial-Kieny (1119_CR24) 2011; 25 MF Aries (1119_CR27) 2016; 9 S Coppola (1119_CR20) 2022 AC Fostini (1119_CR28) 2017; 27 F Lestienne (1119_CR32) 2020; 34 Y Nam (1119_CR23) 2021 MD Thouvenin (1119_CR15) 2018; 17 ML Mangoni (1119_CR10) 2016; 25 HC Korting (1119_CR2) 2011; 25 V Vendrely (1119_CR31) 2022; 12 V Ribet (1119_CR25) 2018; 11 L Sulimovic (1119_CR26) 2002; 28 A Villaret (1119_CR33) 2022; 36 M Deleuran (1119_CR30) 2020; 10 N Gao (1119_CR7) 2010; 5 M Bradley (1119_CR3) 1999; 3 N Golkar (1119_CR21) 2021; 2021 A Pinter (1119_CR14) 2019; 9 A Stedman (1119_CR6) 2016; 32 38831119 - Dermatol Ther (Heidelb). 2024 Jun 3. doi: 10.1007/s13555-024-01167-3 |
| References_xml | – volume: 106 start-page: 5879 year: 2022 end-page: 5891 ident: CR18 article-title: Current postbiotics in the cosmetic market-an update and development opportunities publication-title: Appl Microbiol Biotechnol doi: 10.1007/s00253-022-12116-5 – volume: 11 start-page: 1420 year: 2023 ident: CR17 article-title: Oral and topical probiotics and postbiotics in skincare and dermatological therapy: a concise review publication-title: Microorganisms doi: 10.3390/microorganisms11061420 – year: 2021 ident: CR23 article-title: Improvement of cutaneous wound healing via topical application of heat-killed CAU 1447 on diabetic mice publication-title: Nutrients doi: 10.3390/nu13082666 – volume: 27 start-page: 317 year: 2017 end-page: 318 ident: CR28 article-title: A cream based on Aquaphilus dolomiae extracts alleviates non-histaminergic pruritus in humans publication-title: Eur J Dermatol doi: 10.1684/ejd.2017.2994 – volume: 32 start-page: 983 year: 2016 end-page: 990 ident: CR6 article-title: Microbiota-intestinal stem cells dialog: a key element for intestinal regeneration publication-title: Med Sci (Paris) doi: 10.1051/medsci/20163211014 – volume: 36 start-page: 6 issue: Suppl 5 year: 2022 end-page: 12 ident: CR33 article-title: Clinical evaluation of anaesthetic-like effect of two dermocosmetic formulations containing Aquaphilus dolomiae extract-G3 in subjects with sensitive facial skin publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/jdv.17902 – volume: 32 start-page: 762 year: 2022 end-page: 769 ident: CR13 article-title: Assessment of wound healing efficacy and tolerability using CicatrylTM cream based on a suction blister model in healthy subjects publication-title: Eur J Dermatol doi: 10.1684/ejd.2022.4355 – volume: 135 start-page: 11 year: 2008 end-page: 15 ident: CR34 article-title: Tolerance of the association sucralfate/Cu–Zn salts in radiation dermatitis publication-title: Ann Dermatol Venereol doi: 10.1016/s0151-9638(08)70092-9 – volume: 17 start-page: 1158 year: 2018 end-page: 1164 ident: CR15 article-title: Tolerability and efficacy of a medical device repairing emollient cream in adults with chronic hand dermatitis publication-title: J Cosmet Dermatol doi: 10.1111/jocd.12764 – volume: 3 year: 2008 ident: CR9 article-title: Microbial patterns signaling via toll-like receptors 2 and 5 contribute to epithelial repair, growth and survival publication-title: PLoS ONE doi: 10.1371/journal.pone.0001393 – volume: 34 start-page: 37 issue: Suppl 5 year: 2020 end-page: 42 ident: CR12 article-title: Broad spectrum repairing properties of an extract of Aquaphilus dolomiae on in vitro and ex vivo models of injured skin publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/jdv.16477 – volume: 25 start-page: 2 issue: Suppl 1 year: 2011 end-page: 5 ident: CR24 article-title: Avene thermal spring water: an active component with specific properties publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/j.1468-3083.2010.03892.x – volume: 25 start-page: 130 year: 2011 end-page: 137 ident: CR2 article-title: Management of minor acute cutaneous wounds: importance of wound healing in a moist environment publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/j.1468-3083.2010.03775.x – volume: 20 start-page: 2337 year: 2018 end-page: 2353 ident: CR5 article-title: Host-microbe interaction in the gastrointestinal tract publication-title: Environ Microbiol doi: 10.1111/1462-2920.13926 – volume: 25 start-page: 167 year: 2016 end-page: 173 ident: CR10 article-title: Antimicrobial peptides and wound healing: biological and therapeutic considerations publication-title: Exp Dermatol doi: 10.1111/exd.12929 – year: 2022 ident: CR4 article-title: Innovative treatment strategies to accelerate wound healing: trajectory and recent advancements publication-title: Cells doi: 10.3390/cells11152439 – year: 2022 ident: CR20 article-title: Potential clinical applications of the postbiotic butyrate in human skin diseases publication-title: Molecules doi: 10.3390/molecules27061849 – volume: 14 start-page: 3966 year: 2023 end-page: 3981 ident: CR19 article-title: Probiotics and postbiotics play a role in maintaining dermal health publication-title: Food Funct doi: 10.1039/d3fo00152k – volume: 33 start-page: 165 year: 2016 end-page: 171 ident: CR29 article-title: Effects of a new emollient-based treatment on skin microflora balance and barrier function in children with mild atopic dermatitis publication-title: Pediatr Dermatol doi: 10.1111/pde.12786 – volume: 34 start-page: 43 issue: Suppl 5 year: 2020 end-page: 48 ident: CR32 article-title: Cutaneous sensitivity modulation by Aquaphilus dolomiae extract-G3 on in vitro models of neuro-inflammation publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/jdv.16641 – volume: 11 start-page: 373 year: 2018 end-page: 381 ident: CR25 article-title: A novel dermo-cosmetic product containing thermal spring water, sucralfate, copper sulfate, and zinc sulfate in the management of hand eczema publication-title: Clin Cosmet Investig Dermatol doi: 10.2147/CCID.S157849 – volume: 5 year: 2010 ident: CR7 article-title: Flagellin-induced corneal antimicrobial peptide production and wound repair involve a novel NF-kappaB-independent and EGFR-dependent pathway publication-title: PLoS ONE doi: 10.1371/journal.pone.0009351 – volume: 9 start-page: 264 year: 2023 ident: CR16 article-title: Production, formulation, and application of postbiotics in the treatment of skin conditions publication-title: Fermentation doi: 10.3390/fermentation9030264 – year: 2022 ident: CR22 article-title: Evaluation of a gel containing a propionibacterium extract in an in vivo model of wound healing publication-title: Int J Mol Sci doi: 10.3390/ijms23094708 – volume: 2021 start-page: 8577116 year: 2021 ident: CR21 article-title: A novel effective formulation of bioactive compounds for wound healing: preparation, in vivo characterization, and comparison of various postbiotics cold creams in a rat model publication-title: Evid Based Complement Alternat Med doi: 10.1155/2021/8577116 – volume: 12 start-page: 683 year: 2022 end-page: 699 ident: CR31 article-title: An emollient PLUS balm is useful for the management of xerosis in patients treated for cancer: a real-world, prospective, observational, multicenter study publication-title: Dermatol Ther (Heidelb) doi: 10.1007/s13555-022-00685-2 – volume: 117 start-page: 247 year: 2016 end-page: 258 ident: CR8 article-title: Stimulation of cell migration by Flagellin through the p38 MAP kinase pathway in cultured intestinal epithelial cells publication-title: J Cell Biochem doi: 10.1002/jcb.25272 – volume: 28 start-page: 415 year: 2002 end-page: 418 ident: CR26 article-title: Efficacy and safety of a topically applied Avene spring water spray in the healing of facial skin after laser resurfacing publication-title: Dermatol Surg doi: 10.1097/00042728-200205000-00011 – volume: 62 start-page: 191 year: 2012 end-page: 195 ident: CR11 article-title: Aquaphilus dolomiae gen. nov., sp. nov., isolated from a deep aquifer publication-title: Vie et Milieu – volume: 9 start-page: 421 year: 2016 end-page: 434 ident: CR27 article-title: Anti-inflammatory and immunomodulatory effects of Aquaphilus dolomiae extract on in vitro models publication-title: Clin Cosmet Investig Dermatol doi: 10.2147/ccid.S113180 – volume: 10 start-page: 1013 year: 2020 end-page: 1029 ident: CR30 article-title: An emollient containing Aquaphilus dolomiae extract is effective in the management of xerosis and pruritus: an international, real-world study publication-title: Dermatol Ther (Heidelb) doi: 10.1007/s13555-020-00415-6 – volume: 3 start-page: 1 year: 1999 end-page: 35 ident: CR3 article-title: Systematic reviews of wound care management: (2). Dressings and topical agents used in the healing of chronic wounds publication-title: Health Technol Assess doi: 10.3310/hta3172 – volume: 48 start-page: 651 year: 2015 end-page: 662 ident: CR1 article-title: Current wound healing procedures and potential care publication-title: Mater Sci Eng C Mater Biol Appl doi: 10.1016/j.msec.2014.12.068 – volume: 9 start-page: 309 year: 2019 end-page: 319 ident: CR14 article-title: Tolerability and efficacy of a medical device repairing emollient cream in children and adults with mild to moderate atopic dermatitis publication-title: Dermatol Ther (Heidelb) doi: 10.1007/s13555-019-0295-0 – volume: 135 start-page: 11 year: 2008 ident: 1119_CR34 publication-title: Ann Dermatol Venereol doi: 10.1016/s0151-9638(08)70092-9 – year: 2022 ident: 1119_CR4 publication-title: Cells doi: 10.3390/cells11152439 – volume: 36 start-page: 6 issue: Suppl 5 year: 2022 ident: 1119_CR33 publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/jdv.17902 – volume: 14 start-page: 3966 year: 2023 ident: 1119_CR19 publication-title: Food Funct doi: 10.1039/d3fo00152k – volume: 25 start-page: 2 issue: Suppl 1 year: 2011 ident: 1119_CR24 publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/j.1468-3083.2010.03892.x – volume: 27 start-page: 317 year: 2017 ident: 1119_CR28 publication-title: Eur J Dermatol doi: 10.1684/ejd.2017.2994 – volume: 33 start-page: 165 year: 2016 ident: 1119_CR29 publication-title: Pediatr Dermatol doi: 10.1111/pde.12786 – volume: 10 start-page: 1013 year: 2020 ident: 1119_CR30 publication-title: Dermatol Ther (Heidelb) doi: 10.1007/s13555-020-00415-6 – volume: 32 start-page: 762 year: 2022 ident: 1119_CR13 publication-title: Eur J Dermatol doi: 10.1684/ejd.2022.4355 – volume: 2021 start-page: 8577116 year: 2021 ident: 1119_CR21 publication-title: Evid Based Complement Alternat Med doi: 10.1155/2021/8577116 – volume: 34 start-page: 43 issue: Suppl 5 year: 2020 ident: 1119_CR32 publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/jdv.16641 – volume: 106 start-page: 5879 year: 2022 ident: 1119_CR18 publication-title: Appl Microbiol Biotechnol doi: 10.1007/s00253-022-12116-5 – year: 2021 ident: 1119_CR23 publication-title: Nutrients doi: 10.3390/nu13082666 – year: 2022 ident: 1119_CR22 publication-title: Int J Mol Sci doi: 10.3390/ijms23094708 – volume: 25 start-page: 167 year: 2016 ident: 1119_CR10 publication-title: Exp Dermatol doi: 10.1111/exd.12929 – volume: 20 start-page: 2337 year: 2018 ident: 1119_CR5 publication-title: Environ Microbiol doi: 10.1111/1462-2920.13926 – volume: 11 start-page: 373 year: 2018 ident: 1119_CR25 publication-title: Clin Cosmet Investig Dermatol doi: 10.2147/CCID.S157849 – volume: 25 start-page: 130 year: 2011 ident: 1119_CR2 publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/j.1468-3083.2010.03775.x – volume: 117 start-page: 247 year: 2016 ident: 1119_CR8 publication-title: J Cell Biochem doi: 10.1002/jcb.25272 – volume: 9 start-page: 309 year: 2019 ident: 1119_CR14 publication-title: Dermatol Ther (Heidelb) doi: 10.1007/s13555-019-0295-0 – volume: 3 start-page: 1 year: 1999 ident: 1119_CR3 publication-title: Health Technol Assess doi: 10.3310/hta3172 – volume: 28 start-page: 415 year: 2002 ident: 1119_CR26 publication-title: Dermatol Surg doi: 10.1097/00042728-200205000-00011 – volume: 3 year: 2008 ident: 1119_CR9 publication-title: PLoS ONE doi: 10.1371/journal.pone.0001393 – volume: 62 start-page: 191 year: 2012 ident: 1119_CR11 publication-title: Vie et Milieu – year: 2022 ident: 1119_CR20 publication-title: Molecules doi: 10.3390/molecules27061849 – volume: 9 start-page: 421 year: 2016 ident: 1119_CR27 publication-title: Clin Cosmet Investig Dermatol doi: 10.2147/ccid.S113180 – volume: 17 start-page: 1158 year: 2018 ident: 1119_CR15 publication-title: J Cosmet Dermatol doi: 10.1111/jocd.12764 – volume: 9 start-page: 264 year: 2023 ident: 1119_CR16 publication-title: Fermentation doi: 10.3390/fermentation9030264 – volume: 34 start-page: 37 issue: Suppl 5 year: 2020 ident: 1119_CR12 publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/jdv.16477 – volume: 5 year: 2010 ident: 1119_CR7 publication-title: PLoS ONE doi: 10.1371/journal.pone.0009351 – volume: 48 start-page: 651 year: 2015 ident: 1119_CR1 publication-title: Mater Sci Eng C Mater Biol Appl doi: 10.1016/j.msec.2014.12.068 – volume: 32 start-page: 983 year: 2016 ident: 1119_CR6 publication-title: Med Sci (Paris) doi: 10.1051/medsci/20163211014 – volume: 11 start-page: 1420 year: 2023 ident: 1119_CR17 publication-title: Microorganisms doi: 10.3390/microorganisms11061420 – volume: 12 start-page: 683 year: 2022 ident: 1119_CR31 publication-title: Dermatol Ther (Heidelb) doi: 10.1007/s13555-022-00685-2 – reference: 38831119 - Dermatol Ther (Heidelb). 2024 Jun 3. doi: 10.1007/s13555-024-01167-3 |
| SSID | ssj0000706381 |
| Score | 2.2727435 |
| Snippet | Introduction
In vitro and pre-marketing clinical data have shown the healing properties of a postbiotic extract from
Aquaphilus dolomiae
(ADE-G2). The... In vitro and pre-marketing clinical data have shown the healing properties of a postbiotic extract from Aquaphilus dolomiae (ADE-G2). The effectiveness and... Introduction In vitro and pre-marketing clinical data have shown the healing properties of a postbiotic extract from Aquaphilus dolomiae (ADE-G2). The... IntroductionIn vitro and pre-marketing clinical data have shown the healing properties of a postbiotic extract from Aquaphilus dolomiae (ADE-G2). The... Abstract Introduction In vitro and pre-marketing clinical data have shown the healing properties of a postbiotic extract from Aquaphilus dolomiae (ADE-G2). The... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 697 |
| SubjectTerms | Aquaphilus dolomiae Care and treatment Comparative analysis Dermatologic agents Dermatology Dermocosmetics Formulae, receipts, prescriptions Internal Medicine Medical colleges Medicine Medicine & Public Health Oral and Maxillofacial Surgery Original Research Parents & parenting Personal information Plastic Surgery Population Postbiotics Quality of Life Research Skin Skin healing Skin impairment Soothing User satisfaction Wound healing Wounds and injuries |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k1KQUZC4gAW8SOOc1yqlgqpHKCVerNsx1FX2ialuystv6F_ujNOdrspAi5c17a89oxnvlFmviHkXfCyDhEekgi1Ysr7wIyONatNWZdCaQiisRr5-Js-OlVfz4qzrVZfmBPW0wP3F_cJFKRogqsKI6IqUd8K4ZUvCx0cuLMUrYPP2wqmkg0u0RVjtAUvUjIDgc1QMdPXzYGXxcJkTMDgvGKrkVdK5P2_m-gtH3U3f_LOR9Tkmw4fkYcDqKST_jCPyb3YPiH3j4fP5k_JNSgD_Q6QkKXcGdpTFg92jrq2pifdLF71lN2_aNdQR390IEPYje4DrLygyGLVN5OgABkp9vj10w72o5OfS3d5Pp0t57QGS3oxdZEerBZYfcW-CAqgmGKHL4oFT7D8GTk9PDjZP2JDFwYWdG4WTDlReqFdkJUE8RUeArpcB543oQwhV02pVW1CpRsTmrpyIvAiAMzxjQP0Jxv5nOy0XRtfEiqDMNxVeQGSVLwB8XEnY0TCoFz7GDPC11KwYaAox04ZM3tLroySsyA5myRnVxn5sFlz2RN0_HX2ZxTuZiaSa6cfQOXsoHL2XyqXkfeoGhZNAN6mGyoZ4JBIpmUnYAQBWBllMrI3mglPN4yH18plB9MxtxJBFsAwXWTk7WYYV2I6XBu75dyKSgE0K8E8Z-RFr4ubI0mjAAQLnhEz0tLRmccj7fQ8EYvzRAWkYOOPa4W-_V9_vtTd_3Gpr8gDkR4kpvftkZ3F1TK-Bry38G_S074B6wNMRQ priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgL4k2gICMhcQCLxHEc54SWqqVCKgdopb1ZtuPQlbbJdh_S9jf0TzPjeHdJEb3GtmxnxuPP9sw3hLx3Nq-dh4XEXS2YsNYxJX3NalXWJRcSDtEYjXzyQx6fie_jYhwv3BbRrXJjE4OhrjuHd-Sfc9x7YHeSxZfZJcOsUfi6GlNo3CX3kLoMtbocl9s7FlBnUC88c8G6zJmC402Mm-mj52CvxfBkdMOA5mw92JsChf-_hvqvneqmF-WNp9SwQx09Ig8jtKSjXhcekzu-fULun8TH86fkGlSC_gRgyIIHDe2Ji6O1o6at6Wk39fOeuPuKdg019FcHkoTe6AGAywuKXFZ9SgkKwJFipl876aA_Orpcmdn5ZLpa0Brs6cXEeHq4XmIMFvvGKUBjinm-KIY9QfNn5Ozo8PTgmMVcDMzJVC2ZMLy0XBqXVzkIsbBwrEuly9LGlc6loimlqJWrZKNcU1eGu6xwAHZsYwAD5k3-nOy1XetfEpo7rjJTpYUXAGcawCSZyb1H2qBUWu8Tkm2koF0kKsd8GVO9o1hGyWmQnA6S0-uEfNy2mfU0HbfW_orC3dZEiu3woZv_1nHFarBMReNMVSgOA0VDV3ArbFlIZ2DMaUI-oGpoNAT4N02MZ4BJIqWWHoEpBHilhErI_qAmLGA3LN4ol44GZKF36p6Qd9tibIlOca3vVgvNKwEArQQjnZAXvS5up5QrAVCYZwlRAy0dzHlY0k7OA714FgiBBHT8aaPQu3H9_6e-un0ar8kDHpYauu_tk73lfOXfAJ5b2rdh0f4BMaJFBw priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C24 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1baxQxFA5SQXwR745WiSD4oAMzuU3mcS2tRagP2kLfQpLJ2IXtTLsXqL-hf7rnZLK7Tr2Ar5tkk8y55DvknC-EvPOONz6AITHfiFw453OtQpM3umoqJhQE0ViNfPRVHZ6IL6fyNBWFLdbZ7usryeipt8VucDRiNTFmTZRlnQNyvCsxdscr2lTjEP1vhccwRlpgjTzXENSkapk__83oRIrE_b-751_Op9u5k7cuUOO5dPCQPEiAkk4GDXhE7oTuMbl3lK7Mn5BrUAT6DeBgHvNm6EBXnHwctV1Dj_tZmA903T9p31JLv_cgP5iN7gGkPKfIYDU8JEEBLlJ839dNe5iPTi5X9uJsOlstaANe9HxqA92_WmLlVf6ZUQDEFF_3oljsBMOfkpOD_eO9wzy9wJB7VehlLiyrHFPW85qD6KSDYK5QvixaX3lfiLZSotG-Vq32bVNb5kvpAeK41gLy4y1_Rna6vgsvCOWe6dLWhQwCQEwLSKS0PAQkCyqUCyEj5VoKxid6cnwlY2a2xMooOQOSM1Fy5iojHzZjLgZyjn_2_oTC3fREYu34Qz__YZKdGvBHsvW2lprBQtG9SeaEq6TyFtZcZOQ9qoZB88evaVMVA2wSibTMBBwggCotdEZ2Rz3BbP24ea1cJrmNheEIsACCKZmRt5tmHImpcF3oVwvDagGwrALXnJHngy5utsS1AADMyozokZaO9jxu6aZnkVS8jDRAAib-uFbo7br-_lFf_l_3V-Q-i6aHSXy7ZGc5X4XXgOqW7k004hsaN0JH priority: 102 providerName: Springer Nature |
| Title | The Real-World Effectiveness and Tolerability of a Soothing Cream Containing the Postbiotic Aquaphilus dolomiae Extract-G2 for Skin Healing |
| URI | https://link.springer.com/article/10.1007/s13555-024-01119-x https://www.ncbi.nlm.nih.gov/pubmed/38451421 https://www.proquest.com/docview/3224051265 https://www.proquest.com/docview/2942187073 https://pubmed.ncbi.nlm.nih.gov/PMC10965845 https://doaj.org/article/9635fca9582e47048852b4b756ca0810 |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZdC6UvY_d564IGgz1sHrYsy_LDGGlIWwYpo2sgb0KW5TWQ2m0ukP6G_emdI9vJ3HV72IshkRRdzkWfYp3vEPLOZFFuLBgSMzn3eZYZXwqb-7lM8oRxAYdojEYenYnTMf86iSc7pE131Czg4t6jHeaTGs9nn9Y3t1_A4D9vw-Bg08Q4Y7xPEYapD5hyD3amBDMajBq47zxzghs0nsHATiNfwnGniaO5_2cOyH4kOUAKFna2Lcfu_6cP_20Tu3vB8s5bVrd5HT8iDxvUSfu1mjwmO7Z8QvZHzXv1p-QnaAs9B8zou8s1tOY0bhwh1WVOL6qZndec3re0Kqim3ysQMvRGB4A7ryjSXNXZJihgSopJgLNpBf3R_s1KX19OZ6sFzcHVXk21pcP1EsOz_BNGATVTTAFGMSIKmj8j4-PhxeDUb9I0-EYEculzzZKMCW2iNAL5xhmc-AJhwqAwiTEBLxLBc2lSUUhT5KlmJowN4KCs0AAPoyJ6TnbLqrQvCY0Mk6FOg9hyQDoFwJVQR9Yio1AgMms9ErZSUKbhMMdUGjO1ZV9GISoQonJCVGuPfNi0ua4ZPP5Z-wiFu6mJ7Nvui2r-QzXGrMBpxYXRaSwZDBR9YMwyniWxMBrGHHjkPaqGQq3F1dRNqANMEtm2VB-8JCAvyaVHDjs1wbZNt7hVLtWahooQhQFOE7FH3m6KsSXelytttVooloLOgitOIo-8qHVxM6VWpT0iO1ramXO3pJxeOubx0HEFcej4Y6vQ23H9fVFf_X9Pr8kBcxaJt_4Oye5yvrJvAAYusx55wIMTeCaTpEf2joZn387h04BxfIpBz_290nMeAJ5j1v8FC_9c1Q |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkYAL4k2ggJFAHMAicZzEOSC0lJYt7fYAW2lvruM4dKVtst2H2P4G_gu_kZm8lhTRW6_reG1nxt98E3tmCHllEj81FjYSN6lgIkkMk6FNWSqjNOIiBCcao5EHh2H_SHwdBaMN8ruJhcFrlQ0mlkCdFga_kb_30faAdQqDj9MzhlWj8HS1KaFRqcW-Pf8JLtv8w95nkO9rznd3htt9VlcVYCZ05YIJzaOEh9r4sQ_TCRJwUNzQeG5mImNckUWhSKWJw0yaLI01N15gwGwnmQY242c-_O81ch0Mr4vOXjSK2m86sH1AndHHAxzwmQR3qo7TqaL1wLZjODRe-_C8mK06trAsGfCvYfjLMl68tXnh6La0iLt3yO2aytJepXt3yYbN75Ebg_qw_j75BSpIvwERZeWNHVolSq7Rleo8pcNiYmdVovBzWmRU0-8FaA6MRreBzJ5SzJ1VlbCgQFQpVhZOxgWMR3tnSz09GU-Wc5oCfp-OtaU7qwXGfLEvnAIVp1hXjGKYFXR_QI6uREoPyWZe5PYxob7h0tOxG1gB9CkDDuRp31pMU-SGibUO8RopKFMnRsf6HBO1TumMklMgOVVKTq0c8rbtM63Sglz69CcUbvskpvQufyhmP1SNEAqQMMiMjgPJYaIIrAFPRBIFodEwZ9chb1A1FAIPvk1dx0_AIjGFl-oB9AKdk0I6ZKvzJACG6TY3yqVqwJqr9fZyyMu2GXviJbzcFsu54rEAQhiBUXDIo0oX2yX5UgD15p5DZEdLO2vutuTjkzKduVcmIBIw8LtGodfz-v9LfXL5Ml6Qm_3h4EAd7B3uPyW3eLnt8OrgFtlczJb2GXDJRfK83MCUHF81YvwBJyGCEA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJ028IO4EBhgJxANYSxwncR4Q6raWjbFqGpu0N89xHFZpS7peRPcb-Ef8Os7JpSVD7G2vdVzbOcff-RyfCyFvTeKnxsJG4iYVTCSJYTK0KUtllEZchHCIxmjk_UG4cyy-ngQnK-R3EwuDbpUNJpZAnRYGv5Fv-Gh7wDqFwUZWu0UcbPc_jy4ZVpDCm9amnEalInv26icc3yafdrdB1u847_eOtnZYXWGAmdCVUyY0jxIeauPHPkwtSOCw4obGczMTGeOKLApFKk0cZtJkaay58QIDJjzJNDAbP_Phf--Q1QhPRR2yutkbHBwuvvDAZgLlxhMfoILPJByu6qidKnYPLD0GR6MTiOfFbN6yjGUBgX_NxF928roP57WL3NI-9u-TezWxpd1KEx-QFZs_JGv79dX9I_ILFJIeAi1lpf8OrdIm11hLdZ7So-Lcjqu04Ve0yKim3wvQIxiNbgG1vaCYSasqaEGBtlKsM5wMCxiPdi9nenQ2PJ9NaApofjHUlvbmU4wAY184BWJOscoYxaAr6P6YHN-KnJ6QTl7k9hmhvuHS07EbWAFkKgNG5GnfWkxa5IaJtQ7xGikoU6dJx2od52qZ4Bklp0ByqpScmjvkw6LPqEoScuPTmyjcxZOY4Lv8oRj_UDVeKMDFIDM6DiSHiSLMBjwRSRSERsOcXYe8R9VQCEP4NnUdTQGLxIReqgtADOROCumQ9daTAB-m3dwol6rha6KWm80hbxbN2BNd8nJbzCaKxwLoYQQmwiFPK11cLMmXAog49xwiW1raWnO7JR-elcnNvTIdkYCBPzYKvZzX_1_q85uX8ZqsAVqob7uDvRfkLi93HfoRrpPOdDyzL4FYTpNX9Q6m5PS2QeMPHcGHqw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Real-World+Effectiveness+and+Tolerability+of+a+Soothing+Cream+Containing+the+Postbiotic+Aquaphilus+dolomiae+Extract-G2+for+Skin+Healing&rft.jtitle=Dermatology+and+therapy&rft.au=Shi%2C+Yuling&rft.au=Lain%2C+Edward&rft.au=Frasson%2C+Nicolas&rft.au=Ortiz-Brugu%C3%A9s%2C+Ariadna&rft.date=2024-03-01&rft.pub=Springer+Healthcare&rft.issn=2193-8210&rft.eissn=2190-9172&rft.volume=14&rft.issue=3&rft.spage=697&rft.epage=712&rft_id=info:doi/10.1007%2Fs13555-024-01119-x&rft_id=info%3Apmid%2F38451421&rft.externalDocID=PMC10965845 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2193-8210&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2193-8210&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2193-8210&client=summon |